[go: up one dir, main page]

PE20090437A1 - Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos - Google Patents

Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos

Info

Publication number
PE20090437A1
PE20090437A1 PE2008001137A PE2008001137A PE20090437A1 PE 20090437 A1 PE20090437 A1 PE 20090437A1 PE 2008001137 A PE2008001137 A PE 2008001137A PE 2008001137 A PE2008001137 A PE 2008001137A PE 20090437 A1 PE20090437 A1 PE 20090437A1
Authority
PE
Peru
Prior art keywords
methylpropoxy
pyridin
cycloalkyl
hydroxy
concentrating hormone
Prior art date
Application number
PE2008001137A
Other languages
English (en)
Inventor
Philip D Stein
Sharon N Bisaha
Saleem Ahamad
William N Washburn
Khehyong Ngu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20090437A1 publication Critical patent/PE20090437A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE A ES ANILLO FENILENO, ANILLO HETEROARILO QUE CONTINE UNO DOS ATOMOS DE NITROGENO U OXIGENO; R1 ES Z-Y-X, DONDE X ES O, S, -S(O)- O -S(O)2-; Y ES ENLACE, CICLOALQUILO C3-C6, ALQUILO; Z ES ARILO, HETEROARILO; R2 ES -E-G-(J)m; m ES 1-3; E ES O, S, ENLACE; G ES ALQUILO INFERIOR, FENILALQUILO, CICLOALQUILO, ENTRE OTROS; J ES H, OH, CN, -SR7, -SOR7, ENTRE OTROS; DONDE R7 ES ALQUILO INFERIOR; R3 ES H, ALQUILO C1-C6, CICLOALQUILO, ALCOXI C1-C6, CN, ENTRE OTROS; R8 Y R9 SON CADA UNO H, HALOGENO, ALQUILO. SON COMPUESTOS PREFERIDOS: 1-(4-(2-HIDROXI-2-METILPROPOXI)-3-METOXIFENIL)-3-(2-(PIRIDIN-2-IL)-ETILTIO)PIRAZIN-2(1H)-ONA; 1-(4-(2-HIDROXI-2-METILPROPOXI)-3-METILFENIL)-3-(5-(TRIFLUOROMETIL)PIRIDIN-2-ILTIO)PIRAZIN-2(1H)-ONA; 1-(4-(2-HIDROXI-2-METILPROPOXI)-3-METILFENIL)-3-(2-(PIRIDIN-2-IL)ETILTIO)PIRAZIN-2(1H)-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS NO BASICOS DEL RECEPTOR DE LA HORMONA CONCENTRADORA DE MELANINA 1 (MCRH1) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES TIPO II, ARTERIOESCLEROSIS, OSTEOARTRITIS, HEMOSTASIS DE GLUCOSA ALTERADA, HIPERCOLESTEROLEMIA, ENTRE OTROS
PE2008001137A 2007-07-06 2008-07-04 Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos PE20090437A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94821307P 2007-07-06 2007-07-06
US12/141,228 US20090011994A1 (en) 2007-07-06 2008-06-18 Non-basic melanin concentrating hormone receptor-1 antagonists and methods

Publications (1)

Publication Number Publication Date
PE20090437A1 true PE20090437A1 (es) 2009-04-18

Family

ID=40221936

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001137A PE20090437A1 (es) 2007-07-06 2008-07-04 Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos

Country Status (16)

Country Link
US (3) US20090011994A1 (es)
EP (1) EP2173725A2 (es)
JP (1) JP2010532791A (es)
KR (1) KR20100044824A (es)
CN (1) CN101801938A (es)
AR (1) AR067475A1 (es)
AU (1) AU2008275207A1 (es)
BR (1) BRPI0813580A2 (es)
CA (1) CA2692671A1 (es)
CL (1) CL2008001994A1 (es)
CO (1) CO6270360A2 (es)
EA (1) EA201000157A1 (es)
PE (1) PE20090437A1 (es)
TW (1) TW200906413A (es)
WO (1) WO2009009501A2 (es)
ZA (1) ZA201000055B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
PT2250156E (pt) 2008-03-05 2015-09-09 Merck Patent Gmbh Derivados de pirazinona como estimuladores da secreção de insulina, métodos para a sua obtenção e utilização destes para o tratamento de diabetes
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2010104830A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
CA2774998A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
PH12012500796A1 (en) 2009-10-23 2012-11-26 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
WO2013105676A1 (en) * 2012-01-12 2013-07-18 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN104403460B (zh) * 2014-12-23 2016-06-15 江阴市天邦涂料股份有限公司 一种海水防污水性涂料
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
US10393856B2 (en) * 2016-02-25 2019-08-27 Honeywell International Inc. Using bluetooth beacons to automatically update the location within a portable gas detector's logs
KR102448342B1 (ko) 2016-03-10 2022-09-27 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
US11783600B2 (en) 2019-02-04 2023-10-10 Jungo Connectivity Ltd. Adaptive monitoring of a vehicle using a camera
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
CN120081869A (zh) * 2025-04-30 2025-06-03 西华大学 一种作用胆碱酯酶的药物前药及其制备方法与应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) * 1974-06-07 1981-03-18
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
AU599580B2 (en) 1984-12-04 1990-07-26 Sandoz Ag Indene analogs of mevalonolactone
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
HU205125B (en) 1987-05-22 1992-03-30 Squibb & Sons Inc Process for producing phosphorous compounds and pharmaceutical compositions comprising same
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5447954A (en) * 1992-05-05 1995-09-05 Smithkline Beecham P.L.C. Phenylderivate as inhibitors of ATP citrate lyase
US5712396A (en) * 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
AU2401697A (en) 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
CA2265672C (en) * 1996-09-16 2008-12-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
DE69824194T2 (de) 1997-10-08 2005-01-13 Sankyo Co., Ltd. Substituierte kondensierte heterocyclische verbindungen
DK1094816T3 (da) 1998-07-06 2009-04-06 Bristol Myers Squibb Co Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
AU5612199A (en) 1998-09-10 2000-04-03 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
EP1133308B1 (en) 1998-11-25 2003-11-12 Nutri Pharma ASA Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
WO2000050574A1 (en) 1999-02-24 2000-08-31 Johns Hopkins University Compositions and methods for modulating serum cholesterol
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1966164B1 (en) * 2005-12-21 2013-03-06 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
DK2170848T3 (en) 2007-06-27 2015-01-05 Astrazeneca Ab Pyrazinonderivater and their use to treat lung diseases

Also Published As

Publication number Publication date
WO2009009501A3 (en) 2009-04-02
TW200906413A (en) 2009-02-16
CA2692671A1 (en) 2009-01-15
US8067420B2 (en) 2011-11-29
US8012984B2 (en) 2011-09-06
CO6270360A2 (es) 2011-04-20
CN101801938A (zh) 2010-08-11
US20090011994A1 (en) 2009-01-08
WO2009009501A4 (en) 2009-06-11
CL2008001994A1 (es) 2008-09-22
US20110144060A1 (en) 2011-06-16
AR067475A1 (es) 2009-10-14
KR20100044824A (ko) 2010-04-30
JP2010532791A (ja) 2010-10-14
ZA201000055B (en) 2011-05-25
BRPI0813580A2 (pt) 2014-12-30
WO2009009501A2 (en) 2009-01-15
US20110003759A1 (en) 2011-01-06
AU2008275207A1 (en) 2009-01-15
EP2173725A2 (en) 2010-04-14
EA201000157A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
ATE496043T1 (de) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
AR070797A1 (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7

Legal Events

Date Code Title Description
FC Refusal